GLP-1 receptor agonists likely have little or no effect on obesity-related cancer risk, research shows

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or overweight or obesity.

Continue Reading

News Source: medicalxpress.com